ArticleJournal for immunotherapy of cancer2026
Vaccinia virus armed with IL-21 can cure murine colorectal cancer liver metastases via intravenous administration.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver metastases of colorectal cancer are one of the leading causes of mortality in patients with colorectal cancer. Oncolytic virus immunotherapy has demonstrated significant potential in tumor treatment; however, most oncolytic viruses are currently administered via intratumoral injection, limiting their broader clinical application.
methodsIn this study, we used an oncolytic vaccinia virus VVLΔTK-STCΔN1L-mIL21 expressing interleukin-21 to treat a male BALB/c murine model of colorectal cancer liver metastases (CRLM) via intravenous administration. This approach aimed to explore the feasibility of oncolytic viruses reaching distant tumors through systemic delivery and exerting therapeutic effects, thereby broadening the application scope of oncolytic viruses. We examined the effects of intravenous vaccinia virus treatment on the survival of mice with colorectal cancer liver metastases. Furthermore, we performed comprehensive analyses of the impacts of vaccinia virus therapy on T lymphocytes in these mice using flow cytometry, in vitro interferon (IFN)-γ release assays, and RNA sequencing.
resultsOur findings revealed that VVLΔTK-STCΔN1L-mIL21, when administered intravenously, successfully reached liver tumor foci and persisted for an extended period, significantly prolonging the survival of mice with CRLM. Further analysis showed that VVLΔTK-STCΔN1L-mIL21 treatment promoted the expansion of CD8
conclusionsVVLΔTK-STCΔN1L-mIL21 can effectively reach liver metastases via tail vein injection and exert potent antitumor effects, significantly extending the survival of mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.